NASDAQ : ATRC

AtriCure, Inc.

$35.04 USD

$2.04 (6.18%)

Volume
1.65M
Average Volume
930.62K
Market Capitalization
$1.77B
P/E Ratio
157.70
Dividend Yield
0.00%
Price Target
$53.50
Year High
$43.18
Year Low
$25.36
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$4.22
Company Overview

NASDAQ

Michael H. Carrel

Medical - Instruments & Supplies

Healthcare

ATRC

1350

US

USD

https://www.atricure.com

513 755 4100

04963C209

0001323885

Liquidity Metrics

0.14

4.22

3.19

2.05

0.00

Sales & Valuation

$534.53M

3.12

3.29

33.08

1.11

Profitability

-$0.24

-$11.45M

1.85%

2.12%

2.14%

1.56%

P/E Metrics

157.70

0.13

0.13

Analyst Price Target & Rating

$53.50

$55.00

$44.00

Neutral

3/5

19 Analysts

-34.50%

Financial Health Scores

6.96

8/9

$263.62M

$676.64M

$160.21M

$16.88M

Key Metrics (TTM)

$1.68B

2.95

61.79

4.22

2.14%

2.04%

0.62%

3.02%

$7.22

65 days

Company Executives
Name Title
Karl S. Dahlquist CCEP Chief Legal Officer
Angela L. Wirick Chief Financial Officer
Valerie Storch-Willhaus Vice President of Corporate Marketing & Communications
Justin J. Noznesky Chief Marketing & Strategy Officer
Michael H. Carrel Chief Executive Officer, President & Director
Salvatore Privitera Chief Technical Officer
Douglas J. Seith Chief Operating Officer
Vinayak Doraiswamy Chief Scientific Officer
Poll Results

No votes yet today — be the first to share your view!

About AtriCure, Inc. (NASDAQ:ATRC) Stock

AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other international territories. The company's product line features various ablation technologies. These include Isolator Synergy Clamps, which are single-use radiofrequency products. Its multifunctional pens, such as the MAX Pen, uniquely enable surgeons to evaluate cardiac arrhythmias, conduct temporary pacing, sensing, and stimulation, and perform tissue ablation with a single device. The Coolrail device facilitates the creation of longer linear ablation lines. For varying lengths of linear ablations, the CryoICE Cryoablation System is available. Furthermore, the EPi-Sense Guided Coagulation System ... is a single-use solution for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. AtriCure also provides systems for cardiac appendage management and soft-tissue closure. The AtriClip System is an implantable device accompanied by a disposable applier, while the LARIAT System offers a suture-based solution for soft-tissue closure, compatible with various anatomical shapes. Additionally, AtriCure offers supplementary surgical tools including Lumitip Dissectors, designed to separate tissues for optimal access, Glidepath guides for precise clamp placement, and Subtle Cannulas facilitating access for EPi-Sense catheters. A suite of reusable cardiac surgery instruments, crucial for procedures involving heart valve repair or replacement, is also available. The company distributes its offerings through a combination of independent distributors and direct sales personnel. Founded in 2000, AtriCure maintains its headquarters in Mason, Ohio.

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

2026-07-23 21:40:26

AtriCure, Inc. (ATRC) Q2 2026 Earnings Call Transcript

AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say

2026-07-23 20:01:06

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

AtriCure (ATRC) Q2 Earnings and Revenues Top Estimates

2026-07-23 18:27:13

AtriCure (ATRC) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.02 per share a year ago.

AtriCure Q2 Earnings Call Highlights

2026-07-23 18:07:47

AtriCure NASDAQ: ATRC reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management, appendage management and open ablation franchises while noting continued pressure in minimally invasive ablation.

AtriCure Reports Second Quarter 2026 Financial Results

2026-07-23 16:01:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu.

AtriCure to Announce Second Quarter 2026 Financial Results

2026-07-02 08:00:00

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2026 financial results on Thursday, July 23, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Thursday, July 23, 2026, to discuss its second quarter financial results. Those interested in listeni.

AtriCure to Announce Second Quarter 2026 Financial Results

2026-07-02 08:00:00

[url="]AtriCure, Inc.[/url] ([url="]Nasdaq: ATRC[/url]), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial a

AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?

2026-06-19 08:41:05

AtriCure (ATRC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Frequently Asked Questions

What is the current AtriCure, Inc. (ATRC) stock price?

AtriCure, Inc.(NASDAQ:ATRC) stock price is $35.04 in the last trading session. During the trading session, ATRC stock reached the peak price of $43.18 while $25.36 was the lowest point it dropped to. The percentage change in ATRC stock occurred in the recent session was 6.18% while the dollar amount for the price change in ATRC stock was $2.04.

ATRC's industry and sector of operation?

The NASDAQ listed ATRC is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.

Who are the executives of ATRC?

Karl S. Dahlquist CCEP | Chief Legal Officer
Angela L. Wirick | Chief Financial Officer
Valerie Storch-Willhaus | Vice President of Corporate Marketing & Communications
Justin J. Noznesky | Chief Marketing & Strategy Officer
Michael H. Carrel | Chief Executive Officer, President & Director

How many employees does ATRC have?

Number of ATRC employees currently stands at 1350. ATRC operates from 7555 Innovation Way, Mason, OH 45040, US.

Link for ATRC official website?

Official Website of ATRC is: https://www.atricure.com

How do I contact ATRC?

ATRC could be contacted at phone #513 755 4100 and can also be accessed through its website. ATRC operates from 7555 Innovation Way, Mason, OH 45040, US.

How many shares of ATRC are traded daily?

The average number of ATRC shares traded daily for last 3 months was 930.62K.

What is the market cap of ATRC currently?

The market value of ATRC currently stands at $1.77B with its latest stock price at $35.04